vs
Side-by-side financial comparison of Stoke Therapeutics, Inc. (STOK) and Trip.com Group Ltd (TCOM). Click either name above to swap in a different company.
Trip.com Group Ltd is the larger business by last-quarter revenue ($304.6M vs $158.6M, roughly 1.9× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 27.8%, a 43.4% gap on every dollar of revenue.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
Trip.com Group Limited is a multinational travel agency headquartered in Shanghai, China. It is the largest online travel service provider in the world.
STOK vs TCOM — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $158.6M | $304.6M |
| Net Profit | $112.9M | $84.6M |
| Gross Margin | — | 78.8% |
| Operating Margin | 70.2% | 16.5% |
| Net Margin | 71.2% | 27.8% |
| Revenue YoY | 3661.1% | — |
| Net Profit YoY | 528.0% | — |
| EPS (diluted) | $1.90 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $304.6M | ||
| Q1 25 | $158.6M | — | ||
| Q4 24 | $22.6M | — | ||
| Q2 24 | — | $242.7M | ||
| Q2 23 | $-2.5M | $214.5M | ||
| Q4 22 | — | $100.7M | ||
| Q3 22 | — | $82.7M |
| Q4 25 | — | $84.6M | ||
| Q1 25 | $112.9M | — | ||
| Q4 24 | $-10.5M | — | ||
| Q2 24 | — | $73.8M | ||
| Q2 23 | $-30.7M | $12.6M | ||
| Q4 22 | — | $41.5M | ||
| Q3 22 | — | $152.6M |
| Q4 25 | — | 78.8% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | 81.8% | ||
| Q2 23 | — | 82.0% | ||
| Q4 22 | — | 76.0% | ||
| Q3 22 | — | 75.5% |
| Q4 25 | — | 16.5% | ||
| Q1 25 | 70.2% | — | ||
| Q4 24 | -60.4% | — | ||
| Q2 24 | — | 27.8% | ||
| Q2 23 | 1340.7% | 26.4% | ||
| Q4 22 | — | — | ||
| Q3 22 | — | -4.2% |
| Q4 25 | — | 27.8% | ||
| Q1 25 | 71.2% | — | ||
| Q4 24 | -46.4% | — | ||
| Q2 24 | — | 30.4% | ||
| Q2 23 | 1235.6% | 5.9% | ||
| Q4 22 | — | 41.2% | ||
| Q3 22 | — | 184.6% |
| Q4 25 | — | $0.12 | ||
| Q1 25 | $1.90 | — | ||
| Q4 24 | $-0.15 | — | ||
| Q2 24 | — | $0.11 | ||
| Q2 23 | $-0.69 | $0.02 | ||
| Q4 22 | — | $0.06 | ||
| Q3 22 | — | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.8M | $10.8B |
| Total DebtLower is stronger | — | $4.2B |
| Stockholders' EquityBook value | $350.1M | $23.8B |
| Total Assets | $406.9M | $36.9B |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.8B | ||
| Q1 25 | $274.8M | — | ||
| Q4 24 | $128.0M | — | ||
| Q2 24 | — | $12.4B | ||
| Q2 23 | $192.1M | $7.6B | ||
| Q4 22 | — | $6.2B | ||
| Q3 22 | — | $7.4B |
| Q4 25 | — | $4.2B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | $8.2B | ||
| Q2 23 | — | $7.2B | ||
| Q4 22 | — | $1.8B | ||
| Q3 22 | — | $7.4B |
| Q4 25 | — | $23.8B | ||
| Q1 25 | $350.1M | — | ||
| Q4 24 | $229.0M | — | ||
| Q2 24 | — | $18.1B | ||
| Q2 23 | $190.2M | $16.3B | ||
| Q4 22 | — | $16.3B | ||
| Q3 22 | — | $15.2B |
| Q4 25 | — | $36.9B | ||
| Q1 25 | $406.9M | — | ||
| Q4 24 | $271.6M | — | ||
| Q2 24 | — | $34.2B | ||
| Q2 23 | $256.9M | $30.1B | ||
| Q4 22 | — | $27.8B | ||
| Q3 22 | — | $26.9B |
| Q4 25 | — | 0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | 0.45× | ||
| Q2 23 | — | 0.44× | ||
| Q4 22 | — | 0.11× | ||
| Q3 22 | — | 0.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $131.8M | — |
| Free Cash FlowOCF − Capex | $131.7M | — |
| FCF MarginFCF / Revenue | 83.0% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.17× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q1 25 | $131.8M | — | ||
| Q4 24 | $-23.2M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | $-21.8M | — | ||
| Q4 22 | — | $380.0M | ||
| Q3 22 | — | — |
| Q4 25 | — | — | ||
| Q1 25 | $131.7M | — | ||
| Q4 24 | $-23.2M | — | ||
| Q2 24 | — | — | ||
| Q2 23 | $-22.6M | — | ||
| Q4 22 | — | $308.0M | ||
| Q3 22 | — | — |
| Q4 25 | — | — | ||
| Q1 25 | 83.0% | — | ||
| Q4 24 | -102.7% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | 912.5% | — | ||
| Q4 22 | — | 305.7% | ||
| Q3 22 | — | — |
| Q4 25 | — | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.2% | — | ||
| Q2 24 | — | — | ||
| Q2 23 | -33.8% | — | ||
| Q4 22 | — | 71.5% | ||
| Q3 22 | — | — |
| Q4 25 | — | — | ||
| Q1 25 | 1.17× | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q4 22 | — | 9.15× | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
STOK
Segment breakdown not available.
TCOM
| Others | $273.0M | 90% |
| Other | $31.6M | 10% |
